Quick Takeaways
- John Paul DeJoria filed SCHEDULE 13G/A for Telomir Pharmaceuticals, Inc. Common Stock, no par value (TELO).
- Disclosed ownership: 9.4%.
- Date of event: 31 Dec 2025.
John Paul DeJoria - 31 Dec 2025 SCHEDULE 13G/A Report for Telomir Pharmaceuticals, Inc. Common Stock, no par value (TELO)
- Filing Manager
- John Paul DeJoria
- Reporting Manager
- John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity
- Symbol
- TELO
- Shares outstanding
- 34,382,284 shares
- Disclosed Ownership
- 3,245,000 shares
- Ownership
- 9.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Feb 2026, 21:24:50 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 18 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"John Paul DeJoria disclosed 9.4% ownership in Telomir Pharmaceuticals, Inc. Common Stock, no par value (TELO) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 18 Sep 2025.
- Current filing was accepted on 12 Feb 2026, 21:24.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity | 9.4% | 3,245,000 | 3,245,000 | 0 | /s/ Matthew R. Bair | Matthew R. Bair, Attorney-in-Fact |